CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) |
Common Stock |
Additional Paid-in Capital |
Subscription Receivable |
Accumulated Deficit |
Series Seed Preferred Stock |
Series A convertible preferred stock |
Series A-2 convertible preferred stock |
Series A-3 convertible preferred stock |
Series CF convertible preferred stock |
Series B convertible preferred stock |
Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beginning balance (in share) at Dec. 31, 2019 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 8,223,036 | 126,641 | |||||
| Beginning balance at Dec. 31, 2019 | $ 66 | $ 15,486,050 | $ (22,677) | $ (22,617,702) | $ 2,071 | $ 565 | $ 593 | $ 823 | $ 12 | $ (7,150,199) | |
| Issuance of Series A-3 preferred stock (in shares) | 809,294 | ||||||||||
| Issuance of Series A-3 preferred stock | 428,845 | (117,614) | $ 81 | 311,312 | |||||||
| Issuance of Series B preferred stock (in shares) | 20,754,717 | ||||||||||
| Issuance of Series B preferred stock | 10,997,925 | $ 2,075 | 11,000,000 | ||||||||
| Offering costs | (31,690) | (31,690) | |||||||||
| Fair value of warrant issuances - venture debt | 58,421 | 58,421 | |||||||||
| Stock-based compensation | 49,932 | 49,932 | |||||||||
| Net loss | (1,906,527) | (1,906,527) | |||||||||
| Ending balance at Mar. 31, 2020 | $ 66 | 26,989,483 | (140,291) | (24,524,229) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 12 | $ 2,075 | 2,331,249 |
| Ending balance (in share) at Mar. 31, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 126,641 | 20,754,717 | ||||
| Beginning balance (in share) at Dec. 31, 2019 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 8,223,036 | 126,641 | |||||
| Beginning balance at Dec. 31, 2019 | $ 66 | 15,486,050 | (22,677) | (22,617,702) | $ 2,071 | $ 565 | $ 593 | $ 823 | $ 12 | (7,150,199) | |
| Net loss | (4,174,124) | ||||||||||
| Ending balance at Jun. 30, 2020 | $ 66 | 27,325,862 | (13,454) | (26,791,826) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | 526,939 |
| Ending balance (in share) at Jun. 30, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance (in share) at Mar. 31, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 126,641 | 20,754,717 | ||||
| Beginning balance at Mar. 31, 2020 | $ 66 | 26,989,483 | (140,291) | (24,524,229) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 12 | $ 2,075 | 2,331,249 |
| Issuance of Series CF preferred stock (in shares) | 709,690 | ||||||||||
| Issuance of Series CF preferred stock | 286,447 | $ 71 | 286,518 | ||||||||
| Issuance of Series A-3 preferred stock | 126,837 | 126,837 | |||||||||
| Stock-based compensation | 49,932 | 49,932 | |||||||||
| Net loss | (2,267,597) | (2,267,597) | |||||||||
| Ending balance at Jun. 30, 2020 | $ 66 | 27,325,862 | $ (13,454) | (26,791,826) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | 526,939 |
| Ending balance (in share) at Jun. 30, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance (in share) at Dec. 31, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance at Dec. 31, 2020 | $ 66 | 27,481,995 | (33,345,997) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | (5,857,645) | |
| Stock-based compensation | 36,976 | 36,976 | |||||||||
| Net loss | (3,023,935) | (3,023,935) | |||||||||
| Ending balance at Mar. 31, 2021 | $ 66 | 27,518,971 | (36,369,932) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | (8,844,604) | |
| Ending balance (in share) at Mar. 31, 2021 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance (in share) at Dec. 31, 2020 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance at Dec. 31, 2020 | $ 66 | 27,481,995 | (33,345,997) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | (5,857,645) | |
| Issuance of Series A-3 preferred stock (in shares) | 809,294 | 709,690 | |||||||||
| Conversion of preferred stock into common stock | 6,293 | ||||||||||
| Conversion of debt into common stock | 2,680,289 | ||||||||||
| Conversion of related party notes and payables into common stock | 257,515 | ||||||||||
| Net loss | (13,721,433) | ||||||||||
| Ending balance at Jun. 30, 2021 | $ 1,104 | 51,939,819 | (47,067,430) | 4,873,493 | |||||||
| Ending balance (in share) at Jun. 30, 2021 | 11,044,594 | ||||||||||
| Beginning balance (in share) at Mar. 31, 2021 | 664,167 | 20,714,518 | 5,654,072 | 5,932,742 | 9,032,330 | 836,331 | 20,754,717 | ||||
| Beginning balance at Mar. 31, 2021 | $ 66 | 27,518,971 | (36,369,932) | $ 2,071 | $ 565 | $ 593 | $ 904 | $ 83 | $ 2,075 | (8,844,604) | |
| Conversion of preferred stock into common stock | $ 403 | 5,888 | $ (2,071) | $ (565) | $ (593) | $ (904) | $ (83) | $ (2,075) | |||
| Conversion of preferred stock into common stock (shares) | 4,027,181 | (20,714,518) | (5,654,072) | (5,932,742) | (9,032,330) | (836,331) | (20,754,717) | ||||
| Issuance of common stock in public offering | $ 241 | 9,999,761 | 10,000,002 | ||||||||
| Issuance of common stock in public offering (in shares) | 2,409,639 | ||||||||||
| Offering costs | (2,116,957) | (2,116,957) | |||||||||
| Exercise of over-allotment option | $ 36 | 1,364,961 | 1,364,997 | ||||||||
| Exercise of over-allotment option (in shares) | 361,445 | ||||||||||
| Conversion of debt into common stock | $ 114 | 2,680,175 | 2,680,289 | ||||||||
| Conversion of debt into common stock (in shares) | 1,135,153 | ||||||||||
| Conversion of related party notes and payables into common stock | $ 15 | 257,500 | 257,515 | ||||||||
| Conversion of related party notes and payables into common stock (in shares) | 152,357 | ||||||||||
| Common stock and warrants issued in connection with note | $ 2 | 73,956 | 73,958 | ||||||||
| Common stock and warrants issued in connection with note (in shares) | 20,000 | ||||||||||
| Common stock issued in connection with business combination | $ 219 | 8,025,323 | 8,025,542 | ||||||||
| Common stock issued in connection with business combination (in shares) | 2,192,771 | ||||||||||
| Exercise of warrants | $ 3 | 145,693 | 145,696 | ||||||||
| Exercise of warrants (in shares) | 31,881 | ||||||||||
| Common stock issued pursuant to consulting agreement | $ 5 | 182,995 | 183,000 | ||||||||
| Common stock issued pursuant to consulting agreement (in shares) | 50,000 | ||||||||||
| Stock-based compensation | 3,801,553 | 3,801,553 | |||||||||
| Net loss | (10,697,498) | (10,697,498) | |||||||||
| Ending balance at Jun. 30, 2021 | $ 1,104 | $ 51,939,819 | $ (47,067,430) | $ 4,873,493 | |||||||
| Ending balance (in share) at Jun. 30, 2021 | 11,044,594 |